AEMD Quote, Financials, Valuation and Earnings

QuidelOrtho has a net margin of -- compared to Aethlon Medical's net margin of -25.21%. Aethlon Medical's return on equity of -- beat QuidelOrtho's return on equity of -58.1%.

Aethlon Medical has a consensus price target of $3.88, signalling upside risk potential of 936.96%. On the other hand QuidelOrtho has an analysts' consensus of $51.14 which suggests that it could grow by 41.59%. Given that Aethlon Medical has higher upside potential than QuidelOrtho, analysts believe Aethlon Medical is more attractive than QuidelOrtho.

Aethlon Medical has a beta of 1.804, which suggesting that the stock is 80.435% more volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.097, suggesting its less volatile than the S&P 500 by 90.311%.

Aethlon Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

Aethlon Medical quarterly revenues are --, which are smaller than QuidelOrtho quarterly revenues of $707.8M. Aethlon Medical's net income of -$1.8M is higher than QuidelOrtho's net income of -$178.4M. Notably, Aethlon Medical's price-to-earnings ratio is -- while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical is -- versus 0.87x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Aethlon Medical's net margin of -1226.82%. Aethlon Medical's return on equity of -- beat VolitionRX's return on equity of --.

Aethlon Medical has a consensus price target of $3.88, signalling upside risk potential of 936.96%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 501.2%. Given that Aethlon Medical has higher upside potential than VolitionRX, analysts believe Aethlon Medical is more attractive than VolitionRX.

Aethlon Medical has a beta of 1.804, which suggesting that the stock is 80.435% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Aethlon Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Aethlon Medical quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Aethlon Medical's net income of -$1.8M is higher than VolitionRX's net income of -$5.8M. Notably, Aethlon Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical is -- versus 36.22x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Aethlon Medical's net margin of -4291.67%. Aethlon Medical's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Aethlon Medical has a consensus price target of $3.88, signalling upside risk potential of 936.96%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that Aethlon Medical has higher upside potential than Catheter Precision, analysts believe Aethlon Medical is more attractive than Catheter Precision.

Aethlon Medical has a beta of 1.804, which suggesting that the stock is 80.435% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

Aethlon Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Aethlon Medical quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Aethlon Medical's net income of -$1.8M is higher than Catheter Precision's net income of -$4.1M. Notably, Aethlon Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical is -- versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Aethlon Medical's net margin of -10.04%. Aethlon Medical's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Aethlon Medical has a consensus price target of $3.88, signalling upside risk potential of 936.96%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Aethlon Medical has higher upside potential than Xtant Medical Holdings, analysts believe Aethlon Medical is more attractive than Xtant Medical Holdings.

Aethlon Medical has a beta of 1.804, which suggesting that the stock is 80.435% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Aethlon Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aethlon Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Aethlon Medical quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Aethlon Medical's net income of -$1.8M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Aethlon Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aethlon Medical is -- versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.